BMCS Conformational Design in Drug Discovery 2024 

BMCS Conformational Design in Drug Discovery

Thursday 7th March 2024 – a date for your diary!

GSK Conference Centre, Stevenage, UK

Conformational Design has played a key role in the medicinal chemistry of small molecule clinical candidates over the last 20 years. A key learning from multiple projects supported by experimental free ligand NMR solution conformations and protein-ligand X-ray structures is that the bioactive conformation of potent ligands is highly populated in solution. Ligand rigidification has been particularly successful in the design of selective and potent protein-protein interaction inhibitors and is becoming an increasingly important approach for PROTACs, molecular glues and other new modalities. This new RSC-BMCS event aims at building a community that shares conformational design strategies, technologies, and successful case studies. It will complement other rational drug design events and promote more successful research into future medicines.

Who should attend?
This symposium will provide great learnings for medicinal chemists, computational chemists, structural biologists, biophysicists and NMR analytical chemists with an academic or industry interest in drug discovery. Prior knowledge in conformational design will not be required.

Registration will be open shortly.

Call for Abstracts
Abstract submission for oral presentations and scientific posters will be open shortly.

Exhibition/Sponsor Opportunities

Exhibition Package is priced at £750 and includes:

– One stand personnel
– Stand space with a six foot trestle table and chairs
– Your logo and full promotional page in the pdf of the delegate handbook
– Your logo in the rolling slides, shown during the breaks
– Any additional stand personnel will have to be booked as delegates

Important links and downloads
Twitter hashtag – #ConformationalDesign24

First announcement poster – click here to download 

Confirmed Speakers
Prof. Jan Kihlberg, Uppsala University
Gianni Chessari, Astex Therapeutics
Elisabetta Chiarparin, GlaxoSmithKline
Martin Packer, AstraZeneca UK
Prof. Alessio Ciulli, University of Dundee

Organising Committee
Markus Schade, AstraZeneca (Chair)
Chris Swain, Cambridge MedChem Consulting (Treasurer)
Tim Barrett, GSK
Sharan Bagal, AstraZeneca
Elisabetta Chiarparin, GSK
Mike Hann, GSK (Scientific Host)

Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333